- Clone:
- REA335 | 1B4
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- ICFC, 3D-IF, IF, IHC Glossary
- Select a conjugate:
Related products for GFAP Antibody, anti-human/mouse/rat, REAfinity™
A
B
A
B
Clone REA335 recognizes the human, mouse, and rat glial fibrillary acidic protein (GFAP), the main intermediate filament protein in mature astrocytes and an important component of the cytoskeleton in astrocytes during development. GFAP is expressed exclusively in astrocytes in the central nervous system. It has been shown to be involved in astrocyte functions, which are important during regeneration, synaptic plasticity, and reactive gliosis. Moreover, different subpopulations of astrocytes have been identified, which are likely to have distinctive tasks in brain physiology and pathology, and which are not only classified by their spatial and temporal appearance, but also by their specific expression of intermediate filaments, including distinct GFAP isoforms.
Additional information: Clone REA335 displays negligible binding to Fc receptors.
ALXDRD
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
CD-1® mouse brain tissue postnatal day 5 was dissociated using the Neural Tissue Dissociation Kit (T) and the gentleMACS™ Dissociator. Brain cells were intracellularly stained with Anti-GFAP antibodies or with the corresponding REA Control (I) antibodies (left images) as well as with Anti-GLAST (ACSA-1) antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.